The New Era of Medicine — Advanced Cancer and Gene Therapies

Medical innovation is transforming healthcare.

Treatments that were impossible just a decade ago are now saving lives.

Unfortunately, they are also transforming the economics of healthcare.

Cancer Treatment Has Changed

Traditional chemotherapy is no longer the only option.

Today's treatments include:

• Immunotherapy
• Precision medicine
• Targeted biologics
• CAR-T cell therapy
• Personalized cancer vaccines
• Combination biologic therapies

Many of these therapies dramatically improve outcomes.

They also dramatically increase costs.

Gene Therapy Is Rewriting Medicine

Gene therapy is one of the most exciting advances in healthcare.

Instead of treating symptoms, many therapies attempt to correct the underlying genetic cause of disease.

Some treatments may be administered only once.

Others permanently alter how cells function.

These therapies offer hope for conditions that previously had no effective treatment.

Life-Changing—And Extremely Expensive

Many advanced therapies cost:

• $500,000
• $1 million
• $2 million
• More than $3 million for a single treatment

While these treatments may cure or significantly improve rare diseases, even one case can have a meaningful financial impact on a health plan.

Why This Matters for Employers

Medical innovation is improving lives at an incredible pace.

The challenge is that health plans must finance these breakthroughs.

As more advanced therapies become available, employers need funding strategies capable of absorbing catastrophic claims while maintaining affordable benefits.

This is one reason level-funded plans, self-funded plans, stop-loss insurance, and specialized pharmacy management have become increasingly important.

Looking Ahead

Healthcare will continue evolving.

Cancer treatments will become more personalized.

Gene therapies will expand.

Precision medicine will improve outcomes.

At the same time, employers will need smarter funding strategies to balance innovation with affordability.

Understanding these emerging cost drivers is essential for building sustainable employee health benefits in the years ahead.